Alkermes plc
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
Current Price
$37.48
-2.29%GoodMoat Value
$101.41
170.6% undervaluedProfile
Valuation (TTM)
Market Cap$6.25B
P/E40.90
EV—
P/B3.43
Shares Out166.65M
P/Sales4.00
Revenue$1.56B
EV/EBITDA26.47
Alkermes plc (ALKS) Stock News
ALKS Stock News & Headlines
Latest stock news and headlines for Alkermes plc (ALKS). Stay informed on earnings reports, analyst upgrades and downgrades, market-moving events, and company announcements.
Current stock price: $37.48. Market cap: $6.25B. Sector: Healthcare. Industry: Drug Manufacturers - Specialty & Generic. This page aggregates the latest news articles relevant to ALKS from financial news sources, helping investors stay current on events that may impact Alkermes plc's stock price.
News catalysts can drive significant short-term price movement. Earnings surprises, management changes, product launches, regulatory decisions, and analyst coverage changes all create opportunities and risks. Combine news monitoring with GoodMoat's fundamental analysis, quality scores, and valuation tools for a complete research workflow on Alkermes plc (ALKS).